Ahead of Game 3 of tomorrow’s NBA Finals, watch a group of Golden State Warriors players try (and mostly fail) to pronounce the names of towns in Massachusetts.
A Supreme Court decision on Roe v. Wade is imminent, and the White House is preparing for the response to the monumental decision.
Welcome to night health care, where we follow the latest developments in policies and news concerning your health. For The Hill, we are Peter Sullivan, Nathaniel Weixel and Joseph Choi. Subscribe here.
The White House is preparing for a decision on abortion
The White House is quietly preparing for a Supreme Court decision overturning Roe v. Wade, a back-to-back decision expected this month that will create immediate pressure to react and act.
Members of the administration held listening sessions with state officials, medical organizations, religious leaders and businesses regarding the legal barriers to abortion already in place in some states.
- Focusing on heads of state highlights that the White House doesn’t have many options unless Congress acts.
Show Interest: People who attended those meetings told The Hill they were encouraged by the White House’s attention but awaited concrete details.
“I believe we’re at least setting the stage for a bigger fight that’s going to happen,” said Marsha Jones, executive director of the Afiya Center, an organization dedicated to the health of black women and girls in Texas. “The White House, at least, they’re giving the impression that they’re ready to fight this fight with us.”
How vocal will Biden be? Publicly, President Biden has been largely silent on the issue of abortion in the weeks since his outrage over the Supreme Court’s draft decision tossing out Roe, which was leaked in early May.
Vice President Harris, meanwhile, has become one of the main voices of the administration, hosting a roundtable with religious leaders on abortion rights in Los Angeles on Monday and posting a video on social media. last week saying other rights are at risk if the court overturns the landmark abortion ruling.
Learn more here.
FDA panel winks at Novavax COVID-19 firing
An outside advisory committee has voted overwhelmingly to recommend that the Food and Drug Administration (FDA) authorize a COVID-19 vaccine made by Novavax for use in adults, a decision that could lead to the addition of a fourth vaccine in the American arsenal.
The FDA’s Vaccine Advisory Committee voted 21 to 0, with one abstention. The FDA is not required to follow the panel’s recommendation, although it often does.
- The two-dose Novavax vaccine was about 90% effective in preventing mild, moderate and severe COVID-19 in clinical trials.
- Importantly, the trials were conducted before the omicron variant, and panel members expressed concern about whether the efficacy would hold up to the current variants.
Reaching vaccine holders: Novavax’s vaccine might appeal to people who have been hesitant to receive one of the mRNA vaccines because it was made using a fundamentally different process.
But winning even a small number of eligible people who have not yet been vaccinated could be a difficult task and it is unclear how successful the company will be. The United States has no shortage of doses of any of the Pfizer-BioNTech or Moderna vaccines that have been available for over a year.
Learn more here.
INVITATION TO A VIRTUAL EVENT
Closing gaps in health insurance, Wednesday, June 8 at 1 p.m. ET
A record number of Americans are insured, but many remain vulnerable to large medical expenses, including high premiums, out-of-pocket payments and pre-authorizations. The Hill sits with Majority Whip Jim Clyburn (DS.C.), Rep. David Schweikert (R-Arizona) and more at discuss filling gaps in health insurance. RSVP today.
FOUR DESTINATIONS ADDED TO COVID TRAVEL WARNING LIST
The Centers for Disease Control and Prevention (CDC) has added four destinations to its list of “high risk” travel locations for COVID-19 statistics.
Guyana, Mongolia, Namibia and St. Kitts and Nevis were all considered Level 3 travel risk on Monday, according to the CDC. They were previously classified as level 2, or “moderate” risk.
- The CDC said people should avoid these countries if they are not up to date on COVID-19 vaccinations.
- To be considered a Tier 3 or high-risk destination, countries must have recorded more than 100 new cases of COVID-19 per 100,000 population in the past 28 days.
The new standard: In April, the agency removed all destinations from the Level 4 risk category, saying it would reserve “Level 4” warnings “for special circumstances, such as a rapidly escalating case trajectory or a extremely high number of cases, the emergence of a new variant of concern, or the collapse of the health infrastructure.
Learn more here.
WATCHDOG PRESSES NIH ON FOREIGN FUNDING DISCLOSURES
The Department of Health and Human Services (HHS) Oversight Office released a report on Tuesday that the majority of National Institutes of Health (NIH) grant recipients did not meet federal requirements for financial interest and support. strangers.
The HHS Office of Inspector General (OIG) found that more than two-thirds of recipients — 69% — who conducted NIH-funded research failed to meet at least one federal interest disclosure requirement. foreign financiers, and many also lacked oversight that would ensure the documents they submit to NIH are accurate and complete.
- The report says it is the recipients’ responsibility to ensure that foreign financial interests are disclosed.
- The OIG found that grant recipients did not require their researchers to disclose grants, professional affiliations, or participation in foreign government programs despite recent reminders from the NIH to do so.
A lack of application: However, the report acknowledged that recipients of some grants may not have known they were subject to specific federal requirements and that many – nearly 3 in 4 – lacked training or guidance on disclosing foreign support.
Learn more here.
Warnock urges Schumer to hold vote on insulin bill
Sen. Raphael Warnock (D-Ga.) is pressuring Senate Majority Leader Charles Schumer (DN.Y.) to vote on legislation to lower the cost of insulin.
Warnock faces a tough re-election race this year and has made lowering the cost of insulin a central part of his message.
“I am deeply disappointed that the Senate was unable to vote on this critical legislation before Memorial Day,” Warnock wrote in a letter to Schumer dated Monday.
“Now is the time for action on this critical issue, and we can’t afford to wait any longer,” he wrote.
Different invoices: Warnock has a bill to cap patients’ out-of-pocket expenses for insulin at $35 per month. But the main effort on insulin in the Senate is a measure of the senses. Jeanne Shaheen (DN.H.) and Susan Collins (R-Maine.) that would include a $35 cap on patient costs while also including other measures to reduce the overall price of the drug.
Slippery timeline: Schumer gave his support to talks between Shaheen and Collins in March and then said he planned to hold a vote “as soon as possible after the Easter holidays”, but that timetable has now come and gone.
Collins said Tuesday that she and Shaheen were “close” to introducing their bill.
Learn more here.
WHAT WE READ
- They thought they bought Obamacare plans. What they got was not insurance (Kaiser Health News)
- Manchin wonders if he wants to avoid setting off an Obamacare ticking time bomb. (initiated)
- ‘Testing bottleneck’ for monkeypox jeopardizes containment hope, experts warn (Stat)
STATE BY STATE
- With a new senator, Nebraska abortion opponents are gaining ground (Associated Press)
- California wants to reduce insulin prices by becoming a drugmaker. Can he succeed? (Kaiser Health News)
- First probable case of monkeypox reported in Maricopa County (ABC15)
OP-EDS ON THE HILL
That’s all for today, thanks for reading. Check out The Hill’s healthcare page for the latest news and coverage. Until tomorrow.
SEE THE FULL EDITION HERE